FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

Core Viewpoint - The AI Fund Zhaoshang Frontier Healthcare Stock A (011373) reported a profit of 41.645 million yuan for Q2 2025, with a fund net value growth rate of 7.89% and a total fund size of 570 million yuan as of the end of Q2 2025 [2][12]. Fund Performance - The fund's weighted average profit per share for the reporting period was 0.0404 yuan [2]. - As of July 17, the unit net value was 0.625 yuan [2]. - The fund's performance over various time frames includes a 32.00% growth rate over the last three months, 43.06% over the last six months, and 42.96% over the last year, ranking 22/54 and 21/53 among comparable funds respectively [2]. Fund Management - The fund is managed by Li Jiasun, who oversees four funds, all of which have shown positive returns over the past year [2]. - The fund focuses on sectors with a comparative advantage in certain growth, particularly in innovative drugs, R&D outsourcing, medical devices, and AI healthcare [2]. Risk Metrics - The fund's three-year Sharpe ratio stands at -0.1027, ranking 28/46 among comparable funds [7]. - The maximum drawdown over the last three years was 48.11%, with the largest single-quarter drawdown occurring in Q3 2022 at 26.38% [8]. Investment Strategy - The fund maintains a high stock position, averaging 90.79% over the last three years, with a peak of 94.27% at the end of Q3 2024 [11]. - The fund has a high concentration in its top ten holdings, which have consistently exceeded 60% over the past two years [15].

Group 1 - The innovative drug concept index rose by 2.68%, ranking 9th among concept sectors, with 197 stocks increasing in value [1] - Notable gainers included Chengdu Xian Dao, Weikang Pharmaceutical, and Maiwei Biotech, each reaching a 20% limit up, while Seli Medical, Lisheng Pharmaceutical, and Xinlitai also hit the limit up [1] - The top gainers in percentage terms were Meidi Xi, Shouyao Holdings, and Shenzhou Cell, with increases of 19.00%, 15.54%, and 15.40% respectively [1] Group 2 - The innovative drug sector saw a net inflow of 1.07 billion yuan, with 104 stocks receiving net inflows, and 8 stocks exceeding 100 million yuan in net inflow [2] - Seli Medical led the net inflow with 222 million yuan, followed by Shenzhou Cell, WuXi AppTec, and Xinlitai with net inflows of 217 million yuan, 203 million yuan, and 147 million yuan respectively [2] - The top stocks by net inflow ratio included Han Shang Group, Weikang Pharmaceutical, and Seli Medical, with net inflow ratios of 56.11%, 17.61%, and 17.43% respectively [3] Group 3 - The innovative drug sector's performance was contrasted by the decline of ST Unimed, *ST Suwu, and Guangsheng Tang, which fell by 5.01%, 4.81%, and 4.41% respectively [1][2] - The overall market sentiment reflected a mixed performance across various sectors, with some sectors like military restructuring and AI-related concepts showing positive trends while others like housing inspection and cement concepts experienced slight declines [2]

Group 1 - The CRO concept index rose by 2.61%, ranking 10th among concept sectors, with 55 stocks increasing in value, including Chengdu Xian Dao which hit a 20% limit up [1] - Leading gainers in the CRO sector included MediWest, Haitai Biological, and Boji Pharmaceutical, with increases of 19.00%, 11.93%, and 9.50% respectively [1] - The sector saw a net inflow of 447 million yuan from main funds, with 30 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow [2] Group 2 - Major contributors to net inflow included WuXi AppTec with 203 million yuan, followed by Zhaoyan New Drug, Chengdu Xian Dao, and MediWest with net inflows of 130 million yuan, 126 million yuan, and 107 million yuan respectively [2] - The net inflow ratios for Zhaoyan New Drug, Chengdu Xian Dao, and MediWest were 13.04%, 12.33%, and 11.88% respectively [3] - The trading volume for WuXi AppTec was 20.33 million yuan with a turnover rate of 1.67% [3] Group 3 - The stock Boji Pharmaceutical had a significant increase of 9.50% with a trading volume of 21.40 million yuan [6] - The stock ST Unnamed experienced the largest decline of 5.01% with a trading volume of 96.79 million yuan [6] - The overall performance of the CRO sector indicates strong investor interest and potential growth opportunities within the industry [2][3]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 | 佔有關事件前的現有已發 行股 ...

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 | 佔有關事件前的現有已發 行股 ...

Group 1 - The Shanghai Stock Exchange 180 Equal Weight Index opened low and rose, increasing by 0.47% to 8334.39 points, with a trading volume of 165.144 billion yuan [1] - The Shanghai 180 Equal Weight Index has risen by 2.50% in the past month, 4.91% in the past three months, and 1.28% year-to-date [1] - The index uses an equal-weighting method, providing a more uniform distribution of individual stocks and industry weights compared to the Shanghai 180 Index [1] Group 2 - The top ten holdings of the Shanghai 180 Equal Weight Index include major companies such as China Construction Bank (0.74%), Industrial Fulian (0.71%), and others [1] - The index's holdings are entirely from the Shanghai Stock Exchange, with the industrial sector accounting for 25.53%, financial sector 23.65%, and information technology 11.86% [2] - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December, with a sample adjustment limit of 10% [2]

Group 1 - The innovative drug sector in A-shares and Hong Kong stocks has seen significant gains, with the Tianhong Innovative Drug ETF (517380) rising by 3.63% and many constituent stocks, such as Sangfor and Kexing, increasing by over 10% [1] - The Tianhong Innovative Drug ETF (517380) is the largest in the market, covering both A-shares and Hong Kong stocks, and tracks the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index, which has a cumulative weight of nearly 60% in its top ten constituent stocks [1] - The Biopharmaceutical ETF (159859) also experienced a rise of 1.28%, with a trading volume exceeding 95 million yuan, and notable gains in constituent stocks like Shenzhou Cell and Anke Bio [1][2] Group 2 - The biopharmaceutical ETF (159859) closely tracks the National Securities Biopharmaceutical Index and is currently the largest in its category [2] - A cooperation agreement was signed between the Hunan Provincial Government and the National Administration of Traditional Chinese Medicine to build a national Chinese medicinal material germplasm resource bank, which aims to enhance the sustainable development of traditional Chinese medicine resources [2] - The innovative drug sector remains a key investment focus, driven by improved biotech financing and supportive domestic policies, alongside the positive earnings forecast from WuXi AppTec [2][3] Group 3 - The innovative drug sector's sustainability is supported by ongoing policy backing, enhanced global competitiveness, and the realization of commercial profits [3] - There is a focus on the improving fundamentals of the innovative drug industry chain, with recovery trends observed in overseas orders and domestic business autonomy [3]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年7月15日 | 2,485,141,055 | | ...

Group 1 - Morgan Stanley's short position in WuXi AppTec (02359.HK) increased from 4.13% on July 11 to 4.71% [1] - The long position rose from 7.35% to 9.24% during the same period [1]